SENATE 150118th CongressSubmitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S1081; text: CR S1103)

A resolution honoring the memories of the victims of the senseless attack at the Covenant School on March 27, 2023.

Last Action: 3/30/2023

Actions

2024-07-15Held at the desk.
2024-07-15Received in the House.
2024-07-12Message on Senate action sent to the House.
2024-07-11Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S4537-4538)
2024-07-11Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
2024-07-11Measure laid before Senate by unanimous consent. (consideration: CR S4537-4538)
2023-03-01Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
2023-03-01Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
2023-03-01Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
2023-02-09Committee on the Judiciary. Ordered to be reported without amendment favorably.
2023-01-30Read twice and referred to the Committee on the Judiciary.
2023-01-30Introduced in Senate

CRS Summary

As of 2024-07-11 (55)

Affordable Prescriptions for Patients Act of 2023

This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version.

Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.

Cosponsors (8)

Richard Blumenthal (D-CT)
Chuck Grassley (R-IA)
Richard Durbin (D-IL)
Ted Cruz (R-TX)
Amy Klobuchar (D-MN)
Mike Braun (R-IN)
Peter Welch (D-VT)
Lisa Murkowski (R-AK)

Subjects

Administrative remedies
Civil actions and liability
Competition and antitrust
Consumer affairs
Drug safety, medical device, and laboratory regulation
Federal Trade Commission (FTC)
Health care costs and insurance
Inflation and prices
Intellectual property
Judicial review and appeals
Manufacturing
Prescription drugs

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.